Zdrowie i gospodarka · 30/03/2010

FDA Proposes Changes to Biologics Regulations to Allow for More Flexibility in Constituent Materials

The FDA is proposing to amend its biologics regulations to permit the Director of the CBER or CDER to approve exceptions or alternatives to the regulation for constituent materials, aiming to provide manufacturers with more flexibility in employing advances in science and technology while maintaining public health protections.